SELENOM and glioblastoma: According to the real-time PCR results shown in Figure 4C, we can confidently speak about a significant increase in the mRNA of the endogenous selenoprotein SELENOM by more than 3–5 times compared with the control when treating human glioblastoma cells with 50, 100, and 200 μg of recombinant hSELENOM.